COVID-19 – Update from Senzime

At Senzime, safety and care for our customers and employees is our top priority. Like most companies, we face the challenge of the spread of COVID-19 (the Coronavirus), and thus closely follow the health guidelines of the Swedish Public Health Authority and the World Health Organization (WHO).

Access to components and production capacity has so far not affected Senzime. We work actively to support customers and partners remotely with the help of digital tools.

Financially, we are on a solid foundation and the company's assessment is that we will be able to deliver products and services without interruption throughout the coronavirus pandemic. The basic need for neuromuscular monitoring has not diminished, although we expect non-emergency surgeries to be postponed in order to accommodate emergency surgeries and allow availability of medical personnel. This could potentially affect demand in the short term, but it is too early to comment on this.

An update of Senzime's situation will be communicated if conditions change. 

Senzime’s TetraGraph neuromuscular monitor is a unique digital system designed to address the needs of perioperative monitoring of physiologic data in surgical patients receiving general anesthesia and muscle relaxation using neuromuscular blocking drugs (NMBAs). The TetraGraph stimulates a peripheral nerve and measures, analyzes and displays in real-time the muscle function in surgical patients who receive NMBAs as part of their general anesthetic.

 

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                                                                          

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com     

 

TO THE EDITORS

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399,
info@fnca.se is Certified Adviser for Senzime. www.senzime.com